Sugi Predict

Sugi Predict / Compounds / SCHEMBL12435246

SCHEMBL12435246

SCHEMBL12435246

Cc1nc(O)ccc1C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 3/20 0.39
▸ GABRA1 P14867 1/20 0.39
▸ GABRB2 P47870 1/20 0.39
▸ ALDH1A1 P00352 5/20 0.38
▸ SMN1; SMN2 Q16637 4/20 0.38
▸ TYR P14679 3/20 0.38
▸ TSHR P16473 2/20 0.38
▸ TDP1 Q9NUW8 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ ALOX15 P16050 4/20 0.37
▸ CYP1A2 P05177 2/20 0.37
▸ MAPT P10636 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ ATP2A2 P16615 1/20 0.37
▸ ATP2A3 Q93084 1/20 0.37
▸ CYP2C9 P11712 3/20 0.35
▸ LMNA P02545 2/20 0.35
▸ NR1I2 O75469 1/20 0.35
▸ MIF P14174 1/20 0.35
▸ HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13920277 0.79 CA2 (0.41) CA2GABRA1GABRB2ALDH1A1SMN1; SMN2
SCHEMBL11955219 0.76 SSTR4 (0.41) CA2GABRA1GABRB2ALDH1A1SMN1; SMN2
SCHEMBL17154859 0.76 TSHR (0.35) CA2GABRA1GABRB2ALDH1A1SMN1; SMN2
SCHEMBL19154881 0.76 CA2 (0.38) CA2GABRA1GABRB2ALDH1A1SMN1; SMN2
SCHEMBL21657687 0.75 CA2 (0.34) CA2GABRA1GABRB2ALDH1A1SMN1; SMN2
SCHEMBL12019749 0.73 NOS2 (0.54) GABRA1GABRB2ALDH1A1TSHRMAPT
SCHEMBL11954927 0.73 ALOX5AP (0.31) CA2GABRA1GABRB2ALOX5APFEN1
SCHEMBL10165008 0.73 CHRNB2 (0.33) CA2GABRA1GABRB2TSHRCYP3A4
SCHEMBL24847741 0.72 CA2 (0.39) CA2GABRA1GABRB2ALDH1A1SMN1; SMN2
SCHEMBL24247021 0.72 CA2 (0.35) CA2GABRA1GABRB2ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216378-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2024-07-04 — — US disclosed
US-20230033320-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (CN) 2023-02-02 — — US disclosed
US-11207325-B2 Triazolopyrimidine compounds and uses thereof NOVARTIS AG (CH) 2021-12-28 — — US disclosed
US-20200323859-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) 2020-10-15 — — US disclosed
US-10676479-B2 Imidazolepyridine compounds and uses thereof NOVARTIS AG (CH) 2020-06-09 — — US disclosed
US-20190233426-A1 IMIDAZOLEPYRIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2019-08-01 — — US disclosed
US-20190142837-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2019-05-16 — — US disclosed
US-10220036-B2 Triazolopyrimidine compounds and uses thereof NOVARTIS AG (CH) 2019-03-05 — — US disclosed
US-20170348312-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2017-12-07 — — US disclosed
US-8440702-B2 1,3-oxazolidin -2-one derivatives useful as CETP inhibitors MERCK SHARP & DOHME CORP. (US) 2013-05-14 — — US disclosed
US-20110178059-A1 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-07-21 — — US disclosed
US-7915271-B2 1,3-oxazolidin-2-one derivatives useful as CETP inhibitors MERCK SHARP & DOHME CORP. (US) 2011-03-29 — — US disclosed
US-20090137548-A1 1,3-Oxazolidin-2-One Derivatives Useful as Cetp Inhibitors MERCK SHARP & DOHME LLC 2009-05-28 — — US disclosed
WO-2007079186-A2 1, 3-OXAZOLIDIN-2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS MERCK & CO., INC. (US) 2007-07-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11207325-B2 Triazolopyrimidine compounds and uses thereof EZH2, DOT1L, EED CA2 3176/4885GABRA1 1971/4885GABRB2 2181/4885
US-20190233426-A1 IMIDAZOLEPYRIDINE COMPOUNDS AND USES THEREOF EZH2, DOT1L, BMI1 CA2 2784/4885GABRA1 1190/4885GABRB2 1429/4885
US-20200323859-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF EZH2, DOT1L, EED CA2 3176/4885GABRA1 1971/4885GABRB2 2181/4885
US-10220036-B2 Triazolopyrimidine compounds and uses thereof EZH2, DOT1L, EED CA2 3176/4885GABRA1 1971/4885GABRB2 2181/4885
US-10676479-B2 Imidazolepyridine compounds and uses thereof EZH2, DOT1L, BMI1 CA2 2784/4885GABRA1 1190/4885GABRB2 1429/4885
US-20170348312-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF EZH2, DOT1L, EED CA2 3176/4885GABRA1 1971/4885GABRB2 2181/4885
US-20110178059-A1 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS CETP, MTTP, APOB CA2 4074/4885GABRA1 4446/4885GABRB2 4602/4885
US-20240216378-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF EZH2, DOT1L, EED CA2 3176/4885GABRA1 1971/4885GABRB2 2181/4885
US-20190142837-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF EZH2, DOT1L, EED CA2 3176/4885GABRA1 1971/4885GABRB2 2181/4885
US-20230033320-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF EZH2, DOT1L, EED CA2 3176/4885GABRA1 1971/4885GABRB2 2181/4885
US-20090137548-A1 1,3-Oxazolidin-2-One Derivatives Useful as Cetp Inhibitors CETP, MTTP, APOB CA2 4074/4885GABRA1 4446/4885GABRB2 4602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.